What is Axonics?
Founded in 2012 and headquartered in Irvine, California, Axonics is a specialized medical technology firm focused on the innovation of implantable neuromodulation systems. The company operates at the intersection of biotechnology and advanced engineering, developing proprietary solutions that offer therapeutic alternatives for patients with chronic conditions. By prioritizing clinical efficacy and patient-centric design, Axonics has established itself as a key player in the neuromodulation sector, attracting significant backing from top-tier life sciences investors and venture capital firms that specialize in high-impact healthcare solutions.
How much funding has Axonics raised?
Axonics has raised a total of $251.7M across 5 funding rounds:
Series A
$32.6M
Series B
$38.5M
Series C
$20.5M
Series D
$40.1M
Stock Offering
$120M
Series A (2014): $32.6M with participation from Edmond de Rothschild Investment Partners (EdRIP), Neomed Management, and Legend Capital
Series B (2015): $38.5M led by Andera Partners, Legend Capital, Advent Life Sciences, Neomed Management, Edmond de Rothschild Investment Partners, The Alfred E. Mann Foundation, and Cormorant Asset Management
Series C (2017): $20.5M supported by CICA, Inc, Cormorant Asset Management, and Gilde Healthcare
Series D (2018): $40.1M featuring Gilde Healthcare, Silicon Valley Bank, and Longitude Capital
Stock Issuance/Offering (2018): $120M, investors not publicly disclosed
Key Investors in Axonics
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over 1.4 billion euros across venture, growth, and private equity strategies, focusing on businesses that enable better care at lower costs.
Cormorant Asset Management
A prominent life sciences investment firm with over 3 billion dollars in assets under management, Cormorant focuses on fundamental scientific principles to support innovative companies in the biotech sector.
Neomed Management
An international venture capital firm exclusively focused on the healthcare industry, NeoMed invests in emerging companies with outstanding growth prospects across the pharmaceutical and medical device sectors.
What's next for Axonics?
With the recent infusion of capital, Axonics is poised to transition into a more aggressive phase of market penetration and product development. The strategic allocation of these funds will likely focus on scaling manufacturing capabilities, expanding clinical trial data, and enhancing the commercial infrastructure required to support widespread adoption of its neuromodulation platforms. As the company continues to mature, the focus will shift toward long-term sustainability and the potential for further clinical indications, ensuring that Axonics remains at the forefront of the medical device industry while delivering value to its stakeholders and patients alike.
See full Axonics company page
